The art of repositioning drugs: An interview with NovaLead Pharma’s Supreet Deshpande

Inventing a new drug requires huge financial commitment and it’s a lengthy process until it reaches patients in need. However, discovering a new application of an already clinically-approved drug saves you both time and allows you to fully utilise the power of your existing arsenal. Since the original drug application has a known function and toxicity, drug repurposing saves time and …

Download Presentation: The Advantages of Repositioned Drugs

With healthcare budgets facing increased scrutiny, a cost effective approach to reducing the burden of disease and increasing the productivity of the pharmaceutical industry may be new uses for existing drugs, so called drug repositioning. On the face of it, there are numerous advantages of adopting or integrating a drug repositioning strategy:   Repositioned compounds have the potential to show …

Drug Repurposing Presentation: Finding the therapeutic plausibility of a drug in any indication

To quote from a recent article by Seth Lederman, Co-Founder and CEO of Tonix Pharmaceuticals, "New markets for repurposed drugs could be the key to research and development productivity while products lose patent protection". It is safe to say that all those involved in drug discovery and development are seeking new opportunities and strategies to reduce the risk of drug …

Whitepaper: Drug repurposing through nonhypothesis driven phenotypic screening

Christopher Lipinski, Scientific Advisor, Melior Discovery, Inc. kindly provided this whitepaper on ‘Drug repurposing through nonhypothesis driven phenotypic screening.’ The paper discuss how the pharmaceutical industry must radically evolve its drug discovery tactics from the current unsustainable hypothesisdirected model. Download the whitepaper here for more information > The paper propose here that the most efficient, cost-effective and comprehensive way to …

Is drug repositioning surpassing new brands discovery and development?

Is industry giving more emphasis to recycling and repositioning its compounds instead of discovering and developing truly novel new drugs? Since US FDA added the 505(b)(2) pathway for drug approval 18 years ago, the number of approvals through this amendment has consistently increased, until 2006 when it surpassed the approvals by de novo NDA pathway, designated for proprietary drugs. Many …

Download: ‘Drug repositioning for Alzheimer’s disease: The search for a cure’

Farid Khan, Chief Executive Officer, PharmaKure kindly provided this whitepaper on ‘Drug repositioning for Alzheimer’s disease: The search for a cure.’ The paper suggests that ‘drug repositioning offers great promise for quickly bringing new therapeutic options to patient care’. Download the whitepaper here for more information > Following further research, the paper finds that ‘Existing drugs have been shown to …

Evaluating the Discovering New Therapeutic Uses for Existing Molecules program

In putting the agenda and speakers together for the World Drug Repositioning Congress USA, I came up with a lot of opposing views on the NIH's pilot program on the subject. Of course that for a pilot program, there are no expectations that the project will be flawless, in the meantime it should be targeted to really encourage and set …

Survey on Discovering New Therapeutic Uses for Existing Molecules

Working in conjunction with NCATS, we want to understand the life sciences community’s opinion about the recently launched drug repositioning pilot program – Discovering New Therapeutic Uses for Existing Molecules – spearheaded by NIH’s translational sciences department. Compete the survey now – it will only take a few minute of your time! This brief survey will be used to help …

Academia’s role in drug repositioning: an interview with Dr. S Joshua Swamidass

Dr. S Joshua Swamidass, Assistant Professor, Washington University School of Medicine, took the time to speak with us on the role of academia in the multi-stakeholder collaboration initiatives towards drug repositioning. Download the interview here > We asked Joshua several questions about academia’s role in drug repositioning including: What is the key difference in the way academia and industry approach …

“Crowd sourcing drug development”. Can it really lead to drug repositioning?

After the NCATS pilot program ‘Discovering New Therapeutic Uses for Existing Molecules' was launched in May, a lot has been discussed about its potential and the actual feasibility to reposition one or some of the 58 compounds contributed by the eight big pharma joining the project. Experts in the field of drug repurposing say that there's very little opportunity for …